Rutgers University and Infinity BiologiX
HINJ presented Rutgers University and Infinity BiologiX (IBX) with its HINJ Excellence in Research and Innovation Award for their breakthrough research in developing the “saliva test” to identify COVID-19 (SARS-CoV-2). The award was bestowed during the Research and Development Council of New Jersey’s 41st annual Edison Patent Awards event on November 12.
“HINJ recognizes Rutgers and Infinity BiologiX for pioneering an innovative collection method to expand, accelerate and improve the accuracy of testing to detect patients infected with COVID-19. Congratulations for your contribution to protecting public health – you have made New Jersey proud,” said Dean J. Paranicas, president and chief executive officer of HINJ.
Rutgers-New Brunswick Chancellor Chris Molloy added, “The innovative work of Dr. Brooks and his team typifies the kind of impact that Rutgers’ scholars have every day in health care and a range of other fields that benefit New Jersey, the nation and the world. During this unprecedented time in history, Rutgers is proud to be contributing solutions that help mitigate the spread of Covid-19 around the world.”